First approval for biosimilar infliximab, in South Korea (update)
This article was originally published in Scrip
Executive Summary
South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Johnson/Merck & Co's blockbuster biologic therapy Remicade (infliximab).